The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BTX | -91.58% | -99.91% | -75.5% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +69% |
Eterna Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.
The biotech is bulking up with a new acquisition.
This clinical-stage biotech was one of April's brightest stars.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.06M | 91.2% |
| Gross Margin | -6700.00% | -3582.4% |
| Market Cap | $13.54M | 36.8% |
| Market Cap / Employee | $2.26M | 0.0% |
| Employees | 6 | -25.0% |
| Net Income | -$3.14M | 43.2% |
| EBITDA | -$2.45M | 43.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.32M | 66.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.38M | -99.2% |
| Short Term Debt | $0.22M | -94.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -161.66% | -110.5% |
| Return On Invested Capital | -489.37% | -403.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.53M | -1.0% |
| Operating Free Cash Flow | -$2.53M | -12.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.13 | 8.89 | -1.56 | -1.08 | -62.87% |
| Price to Sales | 9.50 | 25.96 | 17.75 | 19.53 | -68.05% |
| Price to Tangible Book Value | -1.80 | -0.50 | -398.84 | -0.80 | -97.05% |
| Enterprise Value to EBITDA | -11.79 | -5.35 | -3.93 | -2.37 | -81.71% |
| Return on Equity | -302.2% | -1154.2% | -2264.3% | - | |
| Total Debt | $38.47M | $0.68M | $2.88M | $0.59M | -98.79% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
